Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized clinical trial comparing early versus late drug withdrawal combining imaging and multi-Omics.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514732-24-00

Acronym

Re-JIA

Enrollment

328

Registered

2024-10-29

Start date

2025-04-28

Completion date

Unknown

Last updated

2025-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile idiopathic arthritis

Brief summary

Rate of flares: the rate of patients who experience disease flare at any time throughout the study period will be compared between the two arms.

Detailed description

Time to Flare: time from randomization to flare

Interventions

DRUGHumira 40 mg solution for injection in pre-filled pen

DRUGORENCIA 125 mg solution for injection in pre-filled syringe

DRUGEnbrel 50 mg solution for injection in pre-filled syringe

DRUGReumaflex 50 mg/ml soluzione iniettabile

DRUGsiringa preriempita

DRUGORENCIA 250 mg powder for concentrate for solution for infusion

DRUGCosentyx 150 mg solution for injection in pre-filled syringe

DRUGEnbrel 25 mg solution for injection in pre-filled syringe

DRUGSimponi 45 mg/0.45 mL solution for injection in pre-filled pen.

DRUGOlumiant 2 mg film-coated tablets

DRUGJylamvo 2 mg/ml oral solution

DRUGOlumiant 1 mg film-coated tablets

DRUGRoActemra 162 mg solution for injection in pre-filled pen.

DRUGRoActemra 20 mg/mL concentrate for solution for infusion

DRUGCosentyx 75 mg solution for injection in pre-filled syringe

DRUGXELJANZ 5 mg film-coated tablets

DRUGCosentyx 150 mg solution for injection in pre-filled pen

DRUGOlumiant 4 mg film-coated tablets

DRUGEnbrel 25 mg solution for injection in pre-filled pen

DRUGMethotrexate 2

DRUG5 mg film-coated tablets

DRUGXELJANZ 1 mg/mL oral solution

DRUGSimponi 50 mg solution for injection in pre-filled pen.

DRUGSimponi 50 mg solution for injection in pre-filled syringe.

DRUGEnbrel 50 mg solution for injection in pre-filled pen

DRUGHumira 20 mg solution for injection in pre-filled syringe

DRUGHumira 40 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Secondary

Measure	Time frame
Time to Flare: time from randomization to flare	—

Primary

Measure	Time frame
Rate of flares: the rate of patients who experience disease flare at any time throughout the study period will be compared between the two arms.	—

Countries

Belgium, Czechia, Denmark, Italy, Lithuania, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026